AdCom

An independent panel of experts that advises the FDA on the safety, efficacy, and approval of new drugs and medical devices.

An Advisory Committee (AdCom) is an independent panel of scientific, medical, and industry experts convened by the Food and Drug Administration (FDA). The committee reviews clinical trial data for a pending drug, biologic, or medical device and votes on whether to recommend its approval. While the FDA is not legally bound by the committee's vote, it historically follows the recommendation in the vast majority of cases. For biotech and pharmaceutical investors, an AdCom meeting is a high-stakes binary event. A positive vote often leads to a massive surge in the company's stock price, while a negative vote or safety concerns flagged in briefing documents can cause the stock to crash. Investors analyze the briefing documents released a few days prior to the meeting to gauge the committee's likely stance. Because of the extreme volatility surrounding these meetings, options trading and stock halts are common. Investors must be cautious, as even a positive AdCom vote does not guarantee final FDA approval, and any unexpected criticisms raised during the public hearing can permanently damage a drug's commercial prospects.

A clinical-stage biotech company awaits an AdCom review for its new gene therapy. The committee votes 12-2 in favor of approval, causing the stock to jump 45% the following morning on expectations of imminent FDA approval.